Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Crispr Therapeutics AG

NASDAQ: CRSP · Life Sciences · 9 alerts · CIK 1674416

Share price
$40.37Close, Nov 16
Market cap
$3.92B
Shares outstanding
97MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Crispr Therapeutics AG filings on SEC EDGAR ↗

5:35 PM ET Form 4
Insider Selling

Crispr Therapeutics CEO Samarth Kulkarni Sells $2.38M of Stock

Samarth Kulkarni, CEO, sold 47,837 shares of Crispr Therapeutics AG at $49.78 a share, worth $2.38M in total on Oct 19, 2026. Shares held after the trade: 311,899 (-13.3%).

Value
$2.38M
Shares
47,837
Price
$49.78
Role
CEO
Holding change
-13.3%
Trade date
Oct 19, 2026
5:46 PM ET Form 4
Insider Selling

Crispr Therapeutics Director Simeon George Sells $720K of Stock

Simeon George, Director, sold 14,514 shares of Crispr Therapeutics AG at $49.63 a share, worth $720K in total on Oct 14, 2026. Shares held after the trade: 15,486 (-48.4%).

Value
$720K
Shares
14,514
Price
$49.63
Role
Director
Holding change
-48.4%
Trade date
Oct 14, 2026
5:35 PM ET Form 4
Insider Selling

Crispr Therapeutics General Counsel and Secretary James R. Kasinger Sells $51.2K of Stock

James R. Kasinger, General Counsel and Secretary, sold 1,040 shares of Crispr Therapeutics AG at $49.26 a share, worth $51.2K in total on Oct 14, 2026. Shares held after the trade: 95,857 (-1.1%).

Value
$51.2K
Shares
1,040
Price
$49.26
Role
General Counsel and Secretary
Holding change
-1.1%
Trade date
Oct 14, 2026
5:35 PM ET Form 4
Insider Selling

Crispr Therapeutics CEO Samarth Kulkarni Sells $202K of Stock

Samarth Kulkarni, CEO, sold 4,098 shares of Crispr Therapeutics AG at $49.26 a share, worth $202K in total on Oct 14, 2026. Shares held after the trade: 259,736 (-1.6%).

Value
$202K
Shares
4,098
Price
$49.26
Role
CEO
Holding change
-1.6%
Trade date
Oct 14, 2026
5:35 PM ET Form 4
Insider Selling

Crispr Therapeutics General Counsel and Secretary James R. Kasinger Sells $119K of Stock

James R. Kasinger, General Counsel and Secretary, sold 1,990 shares of Crispr Therapeutics AG at $60.04 a share, worth $119K in total on Oct 6, 2026. Shares held after the trade: 94,784 (-2.1%).

Value
$119K
Shares
1,990
Price
$60.04
Role
General Counsel and Secretary
Holding change
-2.1%
Trade date
Oct 6, 2026
5:35 PM ET Form 4
Insider Selling

Crispr Therapeutics General Counsel and Secretary James R. Kasinger Sells $626K of Stock

James R. Kasinger, General Counsel and Secretary, sold 10,400 shares of Crispr Therapeutics AG at $60.24 a share, worth $626K in total on Sep 22, 2026. Shares held after the trade: 94,784 (-9.9%).

Value
$626K
Shares
10,400
Price
$60.24
Role
General Counsel and Secretary
Holding change
-9.9%
Trade date
Sep 22, 2026
6:41 PM ET Form 4
Insider Selling

Crispr Therapeutics Director Ali Behbahani Sells $781K of Stock

Ali Behbahani, Director, sold 13,679 shares of Crispr Therapeutics AG at $57.09 a share, worth $781K in total on Sep 17, 2026. Shares held after the trade: 16,637 (-45.1%).

Value
$781K
Shares
13,679
Price
$57.09
Role
Director
Holding change
-45.1%
Trade date
Sep 17, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.